SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688; “Zai Lab”) today announced that data from a preclinical study of ZL-1503, the company’s internally discovered IL-13/IL-31 bispecific antibody for the treatment of atopic dermatitis (AD), will be presented in a late-breaking oral presentation at the European Academy of Dermatology and Venerology Congress (EADV) 2024 taking place September 25-28 in Amsterdam, Netherlands.

上海和剑桥，马萨诸塞州。-（商业新闻短讯）--Zai实验室有限公司（纳斯达克：ZLAB；香港交易所：9688；“Zai实验室”）今天宣布，该公司内部发现的用于治疗特应性皮炎（AD）的IL-13/IL-31双特异性抗体ZL-1503的临床前研究数据将在9月25日至28日于荷兰阿姆斯特丹举行的2024年欧洲皮肤病和性病学会大会（EADV）上发表。

The results will address the potential of ZL-1503 as a novel treatment for moderate-to-severe atopic dermatitis, as well as other diseases involving the IL-13 and IL-31 pathways..

结果将解决ZL-1503作为中重度特应性皮炎以及涉及IL-13和IL-31途径的其他疾病的新型治疗方法的潜力。。

Medications that inhibit IL-4/IL-13 signaling have markedly improved the therapeutic landscape for AD. However, certain AD symptoms are mediated by IL-31, which is only partially attenuated by IL-4/IL-13 inhibition. As a result, many patients experience slow and modest clinical responses to currently available medications.

抑制IL-4/IL-13信号传导的药物显着改善了AD的治疗前景。然而，某些AD症状是由IL-31介导的，IL-31仅被IL-4/IL-13抑制部分减弱。因此，许多患者对目前可用的药物的临床反应缓慢且适度。

Zai is evaluating the potential of ZL-1503 to inhibit both IL-13 and IL-31 signaling pathways..

Zai正在评估ZL-1503抑制IL-13和IL-31信号通路的潜力。。

“The potential to simultaneously target both inflammatory and pruritogenic pathways is important as it expands treatment options for individuals with atopic dermatitis and other related conditions,” said Rafael G. Amado, M.D., President, Head of Global Research and Development, Zai Lab. “We look forward to sharing preliminary results from our preclinical study of ZL-1503 at EADV 2024.”.

“同时针对炎症和瘙痒途径的潜力很重要，因为它扩大了特应性皮炎和其他相关疾病患者的治疗选择，”Zai实验室全球研究与发展负责人Rafael G.Amado医学博士说。“我们期待着在EADV 2024上分享我们对ZL-1503的临床前研究的初步结果。”。

Details regarding the ZL-1503 oral presentation at EADV 2024 are as follows:

有关ZL-1503在EADV 2024上的口头演示的详细信息如下：

Title: ZL-1503, a Bispecific, Serum Half-life Extended Antibody Targeting Both Inflammatory and Pruritogenic Pathways for Atopic Dermatitis and Other IL-13/IL-31 Related Diseases

标题：ZL-1503，一种针对特应性皮炎和其他IL-13/IL-31相关疾病的炎症和瘙痒途径的双特异性血清半衰期延长抗体

Abstract Number: 7744

摘要编号：7744

Presenter: Linda N. Liu, Senior Vice President, Biologics Discovery, Zai Lab

主持人：Linda N.Liu，Zai实验室生物制剂发现高级副总裁

Presentation date and time: Wednesday, September 25, 2024, 2:30-2:45 p.m. CEST

演示日期和时间：2024年9月25日星期三，CEST下午2:30-2:45

Session code and title: D1T01.1: Late breaking news

会议代码和标题：D1T01.1：最新突发新闻

Session room: Auditorium

会议室：礼堂

About Zai Lab

关于Zai实验室

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease.

Zai Lab（纳斯达克股票代码：ZLAB；香港交易所代码：9688）是一家位于中国和美国的创新型、研究型、商业化生物制药公司。我们专注于发现、开发和商业化创新产品，以解决肿瘤学、免疫学、神经科学和传染病领域严重未满足需求的医疗条件。

Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide..

我们的目标是利用我们的能力和资源，对中国和全球的人类健康产生积极影响。。

For additional information about Zai Lab, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

有关Zai实验室的更多信息，请访问www.zailaboratory.com或通过www.twitter.com/ZaiLab\u Global关注我们。

Zai Lab Forward-Looking Statements

Zai实验室前瞻性声明

This press release contains forward-looking statements relating to our future expectations, plans, and prospects, including, without limitation, statements regarding product candidates in our pipeline including ZL-1503 and related preclinical studies; the potential benefits of ZL-1503; and the potential treatment of atopic dermatitis and other diseases involving the IL-13 and IL-31 pathways.

本新闻稿包含与我们未来的期望，计划和前景有关的前瞻性声明，包括但不限于关于我们管道中候选产品的声明，包括ZL-1503和相关的临床前研究；ZL-1503的潜在益处；以及特应性皮炎和其他涉及IL-13和IL-31途径的疾病的潜在治疗方法。

All statements, other than statements of historical fact, included in this press release are forward-looking statements, and can be identified by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would,” and other similar expressions.

本新闻稿中除历史事实声明外的所有声明均为前瞻性声明，可以用“目标”、“预期”、“相信”、“可能”、“估计”、“预期”、“预测”、“目标”、“打算”、“可能”、“计划”、“可能”、“潜在”、“将”、“将会”等词语和其他类似表达来识别。

Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements.

此类声明构成1995年《私人证券诉讼改革法案》所指的前瞻性声明。前瞻性陈述不是对历史事实的陈述，也不是对未来业绩的保证或保证。前瞻性声明基于截至本新闻稿发布之日我们的预期和假设，并受到固有的不确定性、风险和可能与前瞻性声明所设想的情况有重大差异的情况变化的影响。

We may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and .

我们可能无法实际实现计划、实现意图或达到前瞻性声明中披露的预期或预测，您不应过度依赖这些前瞻性声明。由于各种重要因素，实际结果可能与此类前瞻性声明所示结果存在重大差异，包括但不限于（1）我们成功商业化并从我们批准的产品中产生收入的能力，（2）我们获得运营资金的能力以及。

Our SEC filings can be found on our website at www.zailaboratory.com and the SEC’s website at www.sec.gov.

我们的SEC文件可以在我们的网站www.zailaboratory.com和SEC的网站www.SEC.gov上找到。